Ryan Christensen on Biogen Earnings Growth | NECN Market Analysis

Biogen Reports 15% Earnings Growth, 9% Revenue Gains

Ryan Christensen, account executive at Adviser Investments, has the market analysis for Tuesday, July 24. The Dow Jones Industrial Average and S&P 500 gained 0.8% and 0.5%, respectively, while the NASDAQ Composite declined fractionally. For earnings, we saw Biogen (ticker: BIIB) top expectations with 15% earnings per share growth and 9% revenue advances. BIIB closed the day up nearly 6%. Investors continue to react favorably to Biogen’s stock as the company is scheduled to present clinical trials on its experimental BAN2401 therapy at this week’s Alzheimer’s Association International Conference.

Recent Videos

View All Videos

Adam Johnson Sees the Sunny Side of Stocks’ Slide

Adam Johnson on Cheddar: An Opportunistic View of the Sell-Off

Inflation, Health Tech, And Alcoa’s Strong Q4

Lowell on Fox Business: Traders Looking Beyond Omicron, Inflation

Adviser Investments' logo is a registered trademark of Adviser Investments, LLC.